You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerampanel
Accession NumberDB08883
TypeSmall Molecule
GroupsApproved
DescriptionPerampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
Structure
Thumb
Synonyms
3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
perampanel
pérampanel
Perampanelum
External Identifiers
  • E-2007
  • E2007
  • ER-155055-90
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FycompaTablet, film coated12 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated2 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet2 mg/1OralEisai Inc.2012-10-22Not applicableUs
FycompaTablet, film coated8 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaKitEisai Inc.2012-10-222016-10-13Us
FycompaTablet, film coated6 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated6 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet10 mg/1OralEisai Inc.2012-10-22Not applicableUs
FycompaTablet, film coated10 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet6.0 mgOralEisai Limited2013-06-19Not applicableCanada
FycompaTablet, film coated2 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated4 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet4 mg/1OralEisai Inc.2012-10-22Not applicableUs
FycompaTablet, film coated8 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet2.0 mgOralEisai Limited2013-06-19Not applicableCanada
FycompaTablet, film coated8 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated6 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet8.0 mgOralEisai Limited2013-06-19Not applicableCanada
FycompaTablet12 mg/1OralEisai Inc.2012-10-22Not applicableUs
FycompaTablet, film coated12 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated2 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated4 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet6 mg/1OralEisai Inc.2012-10-22Not applicableUs
FycompaTablet, film coated10 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet12.0 mgOralEisai Limited2013-05-17Not applicableCanada
FycompaTablet, film coated10 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated6 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated12 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet10.0 mgOralEisai Limited2013-06-03Not applicableCanada
FycompaSuspension.5 mg/mLOralEisai Inc.2016-04-30Not applicableUs
FycompaTablet, film coated4 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated4 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet8 mg/1OralEisai Inc.2012-10-22Not applicableUs
FycompaTablet, film coated10 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet4.0 mgOralEisai Limited2013-06-19Not applicableCanada
FycompaTablet, film coated12 mgOralEisai Europe Ltd2012-07-23Not applicableEu
FycompaTablet, film coated8 mgOralEisai Europe Ltd2012-07-23Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Perampanel hydrate
1571982-04-1
Thumb
  • InChI Key: PDWMJDKMSASBNE-UHFFFAOYSA-N
  • Monoisotopic Mass: 1450.517742513
  • Average Mass: 1451.617
DBSALT001824
Categories
UNIIH821664NPK
CAS number380917-97-5
WeightAverage: 349.393
Monoisotopic: 349.121512115
Chemical FormulaC23H15N3O
InChI KeyPRMWGUBFXWROHD-UHFFFAOYSA-N
InChI
InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
IUPAC Name
2-{6'-oxo-1'-phenyl-1',6'-dihydro-[2,3'-bipyridine]-5'-yl}benzonitrile
SMILES
O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationUsed in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
Structured Indications
PharmacodynamicsPerampanel is involved in inhibiting neuronal excitation in the central nervous system leading to such effects as decreased pyschomotor performance.
Mechanism of actionThe exact mechanism of action of perampanel in seizures is not yet determined, but it is known that perampanel decreases neuronal excitation by non-competitive ihibition of the AMPA receptor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glutamate receptor 1Proteinyes
antagonist
HumanP42261 details
Related Articles
AbsorptionAfter oral adminitration, perampanel is absorbed rapidly and completely.
Volume of distribution

The volume of distribution of perampanel was not quantified.

Protein bindingPerampanel is 95-96% plasma protein bound with most binding to the plasma proteins α1-acid glycoprotein and albumin.
Metabolism

Perampanel is highly metabolized by CYP3A4 and/or CYP3A5 primary oxidation and by sequential glucuronidation.

Route of eliminationPerampanel is eliminated mostely in the feces (48%) and to a lesser exten in the urine (22%).
Half lifePerampanel has a long elmination half-life of about 105 hours.
Clearance

In healthy patients, perampanel has a clearance of about 12 mL/min.

ToxicityThe FDA label includes an important warning of serious or life-threatening behavioral and psychiatric adverse reactions including aggression, hostility, irritability, anger, and homicidal thoughts in patients taking perampanel.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethanePerampanel may increase the central nervous system depressant (CNS depressant) activities of 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazolePerampanel may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcepromazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
adipiplonPerampanel may increase the central nervous system depressant (CNS depressant) activities of adipiplon.Investigational
AgomelatinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlfaxalonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilPerampanel may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlphacetylmethadolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlprazolamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Perampanel can be decreased when combined with Amiodarone.Approved, Investigational
AmisulpridePerampanel may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmobarbitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AprepitantThe serum concentration of Perampanel can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazolePerampanel may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArticainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtazanavirThe metabolism of Perampanel can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Perampanel can be decreased when combined with Atomoxetine.Approved
AzaperonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Vet Approved
AzelastinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenPerampanel may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BenperidolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
Benzyl alcoholPerampanel may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BexaroteneThe serum concentration of Perampanel can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Perampanel can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Perampanel can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Perampanel can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazolePerampanel may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BrompheniraminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Withdrawn
BupivacainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironePerampanel may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe serum concentration of Perampanel can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilPerampanel may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Vet Approved
CarisoprodolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CeritinibThe serum concentration of Perampanel can be increased when it is combined with Ceritinib.Approved
CetirizinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydratePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Withdrawn
ChloroprocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChlorphenaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorpromazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixenePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Withdrawn
ChlorzoxazonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CinchocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Perampanel is combined with Citalopram.Approved
ClarithromycinThe metabolism of Perampanel can be decreased when combined with Clarithromycin.Approved
ClemastinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClidiniumPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazolePerampanel may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipraminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClorazepatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Perampanel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CobicistatThe metabolism of Perampanel can be decreased when combined with Cobicistat.Approved
CocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
ConivaptanThe serum concentration of Perampanel can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Perampanel can be decreased when combined with Crizotinib.Approved
CyclizinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclosporineThe metabolism of Perampanel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DabrafenibThe serum concentration of Perampanel can be decreased when it is combined with Dabrafenib.Approved
DantrolenePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazolePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Perampanel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Perampanel can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Perampanel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Perampanel can be decreased when combined with Delavirdine.Approved
deramciclanePerampanel may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Investigational
DesfluranePerampanel may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipraminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Perampanel.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Perampanel is combined with Desvenlafaxine.Approved
DetomidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Perampanel can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniraminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved
DiazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Perampanel.Approved
DifenoxinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Perampanel can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Perampanel can be decreased when combined with Diltiazem.Approved
DimenhydrinatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydraminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DoramectinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DoxepinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxycyclineThe metabolism of Perampanel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEPerampanel may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.Approved, Illicit
DronedaroneThe metabolism of Perampanel can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Perampanel.Approved
DrotebanolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Duloxetine.Approved
DycloninePerampanel may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgoninePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERPerampanel may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.Experimental
EcopipamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzPerampanel may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EnfluranePerampanel may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Vet Approved
EntacaponePerampanel may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Perampanel can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Perampanel can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Perampanel is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Perampanel can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopiclonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl loflazepatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Perampanel.Approved
EtidocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Withdrawn
EtizolamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Perampanel.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Perampanel is combined with Etoperidone.Approved
EtorphinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Perampanel can be decreased when it is combined with Etravirine.Approved
EzogabinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FencamfaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FentanylPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FlibanserinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluconazoleThe metabolism of Perampanel can be decreased when combined with Fluconazole.Approved
FludiazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Fluoxetine.Approved, Vet Approved
FlupentixolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirilenePerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
Fluticasone PropionatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.Approved
FluvoxaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Perampanel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Perampanel can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Perampanel can be decreased when it is combined with Fosphenytoin.Approved
FospropofolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Perampanel can be increased when it is combined with Fusidic Acid.Approved
GabapentinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
gabapentin enacarbilPerampanel may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidPerampanel may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit
GepironePerampanel may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Perampanel.Approved
GlutethimidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GuanfacinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothanePerampanel may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit
HexobarbitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HydrocodonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyzinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
IdelalisibThe serum concentration of Perampanel can be increased when it is combined with Idelalisib.Approved
IloperidonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImatinibThe metabolism of Perampanel can be decreased when combined with Imatinib.Approved
ImipraminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Perampanel is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Perampanel can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Perampanel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluranePerampanel may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsradipineThe metabolism of Perampanel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Perampanel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Perampanel can be increased when it is combined with Ivacaftor.Approved
KetaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
KetoconazoleThe metabolism of Perampanel can be decreased when combined with Ketoconazole.Approved, Investigational
LamotriginePerampanel may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LevetiracetamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved
LevocabastinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
Levomethadyl AcetatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Perampanel is combined with Levomilnacipran.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Perampanel.Approved, Investigational
LevorphanolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LidocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LithiumPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LopinavirThe metabolism of Perampanel can be decreased when combined with Lopinavir.Approved
LoratadinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LovastatinThe metabolism of Perampanel can be decreased when combined with Lovastatin.Approved, Investigational
LoxapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
Lu AA21004Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Perampanel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Perampanel can be decreased when it is combined with Lumacaftor.Approved
LurasidonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Perampanel.Investigational
Magnesium SulfatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Vet Approved
MaprotilinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MeclizinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedetomidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Perampanel.Approved, Investigational
MefloquineThe therapeutic efficacy of Perampanel can be decreased when used in combination with Mefloquine.Approved
MelatoninPerampanel may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved
MepivacainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MesoridazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
MetaxalonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethapyrilenePerampanel may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluranePerampanel may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
MethsuximidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylphenobarbitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetyrosinePerampanel may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Perampanel can be decreased when used in combination with Mianserin.Approved
MidazolamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Perampanel can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Perampanel is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perampanel.Approved, Investigational
MirtazapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Perampanel can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Perampanel can be decreased when it is combined with Modafinil.Approved, Investigational
MolindonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
NabilonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NafcillinThe serum concentration of Perampanel can be decreased when it is combined with Nafcillin.Approved
NalbuphinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NefazodoneThe metabolism of Perampanel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Perampanel can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Perampanel can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Perampanel can be decreased when it is combined with Nevirapine.Approved
NilotinibThe metabolism of Perampanel can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Perampanel.Approved
NitrazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
Nitrous oxidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Perampanel.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Perampanel.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Perampanel.Approved
NormethadonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
OlanzapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Perampanel can be decreased when combined with Olaparib.Approved
OlopatadinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumPerampanel may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrlistatThe serum concentration of Perampanel can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantPerampanel may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OsimertinibThe serum concentration of Perampanel can be increased when it is combined with Osimertinib.Approved
OxazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxcarbazepineThe serum concentration of Oxcarbazepine can be increased when it is combined with Perampanel.Approved
OxetacainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.Investigational
OxprenololPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Perampanel can be increased when it is combined with Palbociclib.Approved
PaliperidonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
ParaldehydePerampanel may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Paroxetine.Approved, Investigational
PentazocinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalThe serum concentration of Perampanel can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerospironePerampanel may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenobarbitalThe serum concentration of Perampanel can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenytoinThe serum concentration of Perampanel can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PipamperonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PipotiazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
PiritramidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PizotifenPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PosaconazoleThe metabolism of Perampanel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePerampanel may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PregabalinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PregnanolonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Pregnanolone.Investigational
PrilocainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneThe serum concentration of Perampanel can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProchlorperazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
ProparacainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PSD502Perampanel may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
QuazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
RaclopridePerampanel may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RanolazineThe metabolism of Perampanel can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilPerampanel may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxipridePerampanel may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
RifabutinThe serum concentration of Perampanel can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Perampanel can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Perampanel can be decreased when it is combined with Rifapentine.Approved
RisperidonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RitonavirThe metabolism of Perampanel can be decreased when combined with Ritonavir.Approved, Investigational
RomifidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopinirolePerampanel may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotinePerampanel may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Perampanel.Approved
S-EthylisothioureaPerampanel may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Experimental
Sage 547Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sage 547.Investigational
SaquinavirThe metabolism of Perampanel can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Perampanel.Approved
ScopolaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SertindolePerampanel may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Perampanel is combined with Sertraline.Approved
SevofluranePerampanel may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Perampanel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Perampanel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Perampanel can be increased when it is combined with Simeprevir.Approved
Sodium oxybatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
St. John's WortThe serum concentration of Perampanel can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
SufentanilPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Perampanel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpiridePerampanel may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SuvorexantPerampanel may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.Approved
TasimelteonPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TelaprevirThe metabolism of Perampanel can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Perampanel can be decreased when combined with Telithromycin.Approved
TemazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TetrabenazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracainePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrodotoxinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
ThiothixenePerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiapridePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Investigational
TiclopidineThe metabolism of Perampanel can be decreased when combined with Ticlopidine.Approved
TiletaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TizanidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TocilizumabThe serum concentration of Perampanel can be decreased when it is combined with Tocilizumab.Approved
TolcaponePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TopiramatePerampanel may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TramadolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylaminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcyprominePerampanel may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TriazolamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
TrifluoperazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TriflupromazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimipraminePerampanel may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
Uc1010Perampanel may increase the central nervous system depressant (CNS depressant) activities of Uc1010.Investigational
Valproic AcidPerampanel may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VenlafaxineThe metabolism of Perampanel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Perampanel can be decreased when combined with Verapamil.Approved
VigabatrinPerampanel may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VoriconazoleThe metabolism of Perampanel can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XylazinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
ZaleplonPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Perampanel is combined with Zimelidine.Withdrawn
ZiprasidonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopiclonePerampanel may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved
ZuclopenthixolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Food slows perampanel's absorption rate but not extent.
References
Synthesis Reference

Francesco Fontana, “METHODS FOR PREPARING INTERMEDIATES OF PERAMPANEL.” U.S. Patent US20130109862, issued May 02, 2013.

US20130109862
General References
  1. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y: Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011 Jul;52(7):1331-40. doi: 10.1111/j.1528-1167.2011.03109.x. Epub 2011 Jun 2. [PubMed:21635236 ]
External Links
ATC CodesN03AX22
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (611 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit
SuspensionOral.5 mg/mL
TabletOral10 mg/1
TabletOral10.0 mg
TabletOral12 mg/1
TabletOral12.0 mg
TabletOral2 mg/1
TabletOral2.0 mg
TabletOral4 mg/1
TabletOral4.0 mg
TabletOral6 mg/1
TabletOral6.0 mg
TabletOral8 mg/1
TabletOral8.0 mg
Tablet, film coatedOral10 mg
Tablet, film coatedOral12 mg
Tablet, film coatedOral2 mg
Tablet, film coatedOral4 mg
Tablet, film coatedOral6 mg
Tablet, film coatedOral8 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6949571 No2001-06-082021-06-08Us
US8772497 No2006-05-162026-05-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insoluble in water.From FDA label.
Predicted Properties
PropertyValueSource
Water Solubility0.0056 mg/mLALOGPS
logP3.54ALOGPS
logP4.11ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)4.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.99 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.74 m3·mol-1ChemAxon
Polarizability38.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassBipyridines and oligopyridines
Direct ParentBipyridines and oligopyridines
Alternative Parents
Substituents
  • Bipyridine
  • 3-phenylpyridine
  • Benzonitrile
  • Dihydropyridine
  • Pyridinone
  • Monocyclic benzene moiety
  • Hydropyridine
  • Benzenoid
  • Heteroaromatic compound
  • Lactam
  • Nitrile
  • Carbonitrile
  • Azacycle
  • Organooxygen compound
  • Organonitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Cyanide
  • Organic oxygen compound
  • Organic nitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y: Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011 Jul;52(7):1331-40. doi: 10.1111/j.1528-1167.2011.03109.x. Epub 2011 Jun 2. [PubMed:21635236 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
Comments
comments powered by Disqus
Drug created on May 21, 2013 19:44 / Updated on December 03, 2016 02:46